Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 March 2020 | Story Leonie Bolleurs | Photo Supplied
Solar car Team
Excited about a first for the UFS, Team UFS is entering the 2020 Sasol Solar Challenge. From the left, front, are: Fouché Blignaut, Mechatronic Engineering; Nathan Bernstein, Agricultural Engineering; Lucas Erasmus, Physics; middle: Barend Crous, Manufacturing and Instrumentation; Hendrik van Heerden, Physics (team leader); Antonie Fourie, Physics; Prof Danie Vermeulen, Dean of the Faculty of Natural and Agricultural Sciences (team director); Prof Koos Terblans, Head of the Department of Physics; Theo Gropp, Mechanical Engineering; back: Louis Lagrange, Head of the Department of Engineering; and Mark Jacson, Electronics.

An interdepartmental team from the University of the Free State (UFS) has announced that it will enter and participate in the 2020 Sasol Solar Challenge, scheduled to take place from 11 to 19 September this year. 

For the challenge, Team UFS will build a self-propelled manned vehicle that uses solar power systems to travel from point A to point B. The 14-member team of the UFS will travel on public roads from Pretoria to Cape Town via a predefined route over eight days. They will compete against more than 15 other teams, both local and international. The team that finishes with the greatest distance covered within the allotted time, will win the race. Teams will race every day between 07:30 and 17:00.

The four drivers to operate the vehicles will be selected from participating UFS departments in the coming months.

First solar car for the UFS
Dr Hendrik van Heerden from the Department of Physics has been planning the solar car project – Lengau (meaning Cheetah in Sesotho) – over the past year. He will start assembling the car in the next month together with colleagues and students from both the Departments of Physics and Engineering Sciences (EnSci).

Not only is this a dream come true, but it is also an opportunity for the UFS to show that they can do this. “We do not need the backing of a large and long-established engineering department to build a car like this, a young and vibrant team can do just as much!”, says Dr Van Heerden, who plans to complete the car within a few months, ready to be calibrated and tested later in June.

Capacity in green and sustainable engineering
“The ability of Team UFS to participate is possible due to recent research developments on photovoltaic technologies (solar cells) in the Department of Physics, a well-established leader in the field of surface and material sciences. The university also has established capacity in the fields of photoluminescence and nanomaterials (nanomaterials in energy storage). Additionally, with the establishment of EnSci, the university has expanded into this field, which will bring building capacity in the area of green and sustainable engineering to the project,” says Dr Van Heerden.

Promoting development into green technologies and 4IR
According to Dr Van Heerden, it is clear that the university wishes to become a strong role player in the development and utilisation of green energy, as can be seen in the implementation of relevant technologies on its various campuses. “Thus, for the UFS to be recognised in this research area, it is important to participate in related ‘green’ events where staff and students can build their capacity of practical knowledge by constructing participation equipment such as the solar car.”

He believes that this project has the potential to become a strong base for student training and capacity building in all technological fields, which can promote base development to 4IR.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept